Venture capitalists invested $19.6 million in Maryland companies in the third quarter, the lowest total in any quarter since 1997.
The total investment represents a 76 percent decrease from the second quarter and is down 86 percent from the third quarter last year, according to a MoneyTree Report from PricewaterhouseCoopers LLP and the National Venture Capital Association, based on data provided by Thomson Reuters.
MD Start, a European medical technology accelerator, announced Thursday that it has raised $11.5 million to create and fund four new French companies that can fulfill unmet needs in the medical device market.
The round was led by French Tech Acceleration Fund managed by Bpifrance, a French public investment bank. Other returning investors were French venture capital firm Sofinnova Partners, Dublin-based Medtronic, and LivaNova, a London-based medical device company.
An affiliate of Alexandria Real Estate Equities Inc. (NYSE: ARE), an urban office REIT based in Pasadena, Calif., has purchased Torrey Ridge Science Center in San Diego’s Torrey Pines submarket. Walton Street Capital and SteelWave sold the campus to Alexandria for $182.5 million.
Torrey Ridge Science Center is a Class A life science campus leased to companies such as Regulus Therapeutics, Pacira Pharmaceuticals, Nitto BioPharma, Interpreta and BP Technology Ventures. The three-building, 291,799-square-foot campus was 87 percent leased at the time of sale.
The Johns Hopkins University earned $58 million in licensing revenue in its 2016 fiscal year, three times more than in the prior year.
Johns Hopkins Technology Ventures, the university’s commercialization office, attributed the spike in part to a major sublicensing deal between one of its portfolio companies, Immunomic Therapeutics, and Japanese pharmaceutical company Astellas Pharma.
The Washington DC/Baltimore Chapter of Women In Bio is presenting a program to learn about board service in the public and private sectors. If you are a budding entrepreneur looking to develop a board, this is the event for you. If you were recently named to a board and want to know more about your responsibilities, this is the event for you. If you want to start a business/nonprofit and need to know how to set up a board, this is the event for you.
Wed, Nov 16, 2016 at 6:00 PM
Five Top Intellectual Property Legal Experts and a Room Filled with Life Science and Healthcare Entrepreneurs…what could possibly happen?
Strategies for Start-ups (and Non-Start-ups) to Maintain, Protect and Unlock their Intellectual Property
The workshop is intended for non-lawyers to understand IP issues and answer questions on just about every aspect of IP including; Copyrights, Trade Secrets, Trademarks, Patents, licensing, IP Due Diligence, IP Strategy, etc.
NATURE OF WORK
The Senior Grants and Contracts Manager will be tasked with the preparation, drafting, review and negotiation of contractual agreements with a special emphasis on agreements that support biomedical research initiatives and partnerships. S/he should have a strong customer service orientation and be able to identify process improvements so that transactions are completed with the right balance of efficiency and risk mitigation. S/he will report to the Director of Operations but will serve the contracting needs of colleagues across the Foundation. Strong writing, analytical and organizational skills must be matched with a sense of flexibility, entrepreneurial spirit and good cheer.
Technologists and entrepreneurs are reshaping cities like Baltimore with companies that bring new residents and products that change how we interact with the landscape. With a new mayor set to take office in Baltimore following the November 8 general election, it’s worth considering what the tech community wants to see at City Hall.
Ike Leggett says he will not seek a fourth term as Montgomery County executive.
Leggett, a former Howard University law professor who became the county’s first African American councilman and county executive, first announced publicly Sunday he would not run again at a fundraiser for an anti-term-limits group.
The Rockville biotech says two versions of its ADHD drug could serve a potential $7 billion market.
